Alexion Pharma (ALXN) Tops Q2 EPS by 5c; Updates FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alexion Reports Second Quarter 2015 Results
July 30, 2015 6:30 AM EDTSoliris® (eculizumab) Net Product Sales of $636 Million; Increased 24% Year-on-Year Despite Currency Headwinds; 31% Volume Increase Year-on-Year
2015 Revenue Guidance Increased Reflecting Strong Growth of Soliris in PNH and aHUS
Positive CHMP Opinions Received for Strensiq (asfotase alfa) for Hypophosphatasia (HPP) and Kanuma (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL-D) in the European Union
Strensiq Approved in Japan; Kanuma NDA Filed in Japan
Exceeded Target Enrollment in Eculizumab Refractory Myasthenia Gravis Registration Trial
Completed Synageva Acquisition
CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:... More
